Analysts’ third quarter revenue forecasts were right on the money for Merck KGaA (MRK: DE), the German drugmaker reporting sales of 4.4 billion euros ($5.2 billion), an increase of 9.7%.
The firm announced earnings per share (EPS) of 1.85 euros, up 0.79 euros from the same period of 2019.
The positive outcome was driven largely by a double-digit percentage growth in the firm’s life sciences business sector. Strong demand for Merck’s biotech services also lifted sales, as firms scramble to develop therapies to combat the global coronavirus pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze